<p>
    ABO-Incompatible Liver Transplant Protocol:
</p>
<p>
    ABO-incompatible liver transplantation is only used in urgent or time-sensitive cases where no ABO-compatible graft is available such as in the following conditions:
</p>
<ul>
    <li data-list-item-id="ea320194096b00f776bd7f5006debd866">
         Fulminant hepatic failure (F3/F4) with no compatible donor available
    </li>
    <li data-list-item-id="e77ca5e9b5e8ce5bf69a7f3392a23a9c3">
         Advanced hepatocellular carcinoma (HCC) where transplant must be done quickly and only an ABO-incompatible living donor is available
    </li>
</ul>
<p>
    Because the donor and recipient have mismatched blood group antigens, the recipient’s immune system can rapidly attack the graft. This protocol uses aggressive immunosuppression and antibody removal to reduce the risk of hyperacute rejection.
</p>
<p>
    1. <strong>Pre-Transplant Preparation</strong>
</p>
<ul>
    <li data-list-item-id="eec82ba226b95eafcb8c1d4ed6db34e64">
         <strong>Splenectomy </strong>planned at time of transplant (reduces antibody-producing B cells)
    </li>
    <li data-list-item-id="e47f4a156ff26067e8fdf98d8fb9bb982">
         <strong>Rituximab </strong>375–500 mg/m² IV <strong>1–2 weeks before transplant</strong>
        <ul>
            <li data-list-item-id="ed41346713fab0b75cc48aaf84fde07d0">
                 Rationale: targets CD20+ B cells to prevent new antibody production
            </li>
        </ul>
    </li>
    <li data-list-item-id="eb65b32bfdcad7053f1aeb4295c35c188">
         <strong>Plasmapheresis before surgery</strong> if baseline anti-A/B antibody titer &gt; 1:16
        <ul>
            <li data-list-item-id="ee515f6dd6ffcd7a5ffefec0185e1ab09">
                 Daily × 3 days to reduce antibody levels
            </li>
        </ul>
    </li>
</ul>
<p>
    &nbsp;2. <strong>Immunosuppression Strategy</strong>
</p>
<ul>
    <li data-list-item-id="e06e25612f05e03c183b4e6941c188e59">
         <strong>Prednisone</strong>: standard post-transplant steroid taper
    </li>
    <li data-list-item-id="ee762f641bf08dab8596b1a5b795b2cf2">
         <strong>Tacrolimus</strong>: start early, <strong>higher trough targets</strong> (10–12 ng/mL) to suppress rejection risk
    </li>
    <li data-list-item-id="ef2b5fcf3f3a66d7713291f5ac93c5444">
         <strong>Myfortic</strong>: 540–720 mg BID to provide additional immunosuppressive coverage
    </li>
    <li data-list-item-id="e2c3ef9a9cd7354bae52c75b1aa68bcea">
         <strong>Basiliximab</strong>: 20 mg IV on day 0 and day 4 (IL-2 receptor blocker)
    </li>
    <li data-list-item-id="e46c88d5729ee20796b58bbb9fe29aee7">
         Consider <strong>sirolimus </strong>if rejection is difficult to control despite above regimen
    </li>
</ul>
<p>
    3. <strong>Post-Transplant Antibody Control</strong>
</p>
<ul>
    <li data-list-item-id="efed9313741006227969d2517175b7811">
         <strong>Plasmapheresis daily</strong> until anti-A/B antibody titer &lt; 1:8
    </li>
    <li data-list-item-id="ea2ad9cb0832c7d1fdf748892688995de">
         <strong>IVIG </strong>0.8–1 g/kg daily × 5 days during plasmapheresis
        <ul>
            <li data-list-item-id="e2dd4c8d91a5f9f45c7653fdac03116cc">
                 Rationale: blocks residual antibodies and modulates immune response
            </li>
        </ul>
    </li>
</ul>
<p>
    <strong>Key Monitoring</strong>
</p>
<ul>
    <li data-list-item-id="eebbe553115a62ac9b76062d3080f02f8">
         Daily antibody titers
    </li>
    <li data-list-item-id="eb40da9ccf7a60a7206e2c258ab533538">
         Tacrolimus troughs
    </li>
    <li data-list-item-id="e82ba5737016e188a04738059a57c2739">
         CBC, renal function, and liver function tests&nbsp;
    </li>
</ul>
<img class="img-fluid mx-auto d-block" src="pages/images/06_03.png"/>